Y-mAbs Therapeutics (YMAB) Competitors

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Does the MarketBeat Community believe in CALT or YMAB?

Y-mAbs Therapeutics received 108 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 63.38% of users gave Y-mAbs Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

Company	Underperform	Outperform
Calliditas Therapeutics AB (publ)	Outperform Votes 27 55.10%	Underperform Votes 22 44.90%
Y-mAbs Therapeutics	Outperform Votes 135 63.38%	Underperform Votes 78 36.62%

Do insiders and institutionals hold more shares of CALT or YMAB?

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is CALT or YMAB more profitable?

Y-mAbs Therapeutics has a net margin of -28.22% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Y-mAbs Therapeutics' return on equity of -24.61% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Y-mAbs Therapeutics	-28.22%	-24.61%	-18.49%

Which has higher valuation and earnings, CALT or YMAB?

Y-mAbs Therapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	-21.62
Y-mAbs Therapeutics	$84.82M	3.25	-$21.43M	-$0.54	-11.41

Do analysts recommend CALT or YMAB?

Calliditas Therapeutics AB (publ) currently has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Y-mAbs Therapeutics has a consensus price target of $20.89, suggesting a potential upside of 239.11%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Y-mAbs Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Which has more volatility and risk, CALT or YMAB?

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Does the media refer more to CALT or YMAB?

In the previous week, Y-mAbs Therapeutics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Y-mAbs Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Y-mAbs Therapeutics' average media sentiment score of 0.16 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Y-mAbs Therapeutics	Neutral

Summary

Y-mAbs Therapeutics beats Calliditas Therapeutics AB (publ) on 17 of the 19 factors compared between the two stocks.